Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors
A Phase 1/Phase 2 Study Of CP-751,871 In Patients With Relapsed And/Or Refractory Ewing's Sarcoma Family Of Tumors
Status: Enrolling
Updated:  10/6/2015
Pfizer Investigational Site
mi
from
Providence, RI
Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors
A Phase 1/Phase 2 Study Of CP-751,871 In Patients With Relapsed And/Or Refractory Ewing's Sarcoma Family Of Tumors
Status: Enrolling
Updated: 10/6/2015
Pfizer Investigational Site
mi
from
Providence, RI
Click here to add this to my saved trials
Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors
A Phase 1/Phase 2 Study Of CP-751,871 In Patients With Relapsed And/Or Refractory Ewing's Sarcoma Family Of Tumors
Status: Enrolling
Updated:  10/6/2015
Pfizer Investigational Site
mi
from
Memphis, TN
Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors
A Phase 1/Phase 2 Study Of CP-751,871 In Patients With Relapsed And/Or Refractory Ewing's Sarcoma Family Of Tumors
Status: Enrolling
Updated: 10/6/2015
Pfizer Investigational Site
mi
from
Memphis, TN
Click here to add this to my saved trials
Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors
A Phase 1/Phase 2 Study Of CP-751,871 In Patients With Relapsed And/Or Refractory Ewing's Sarcoma Family Of Tumors
Status: Enrolling
Updated:  10/6/2015
Pfizer Investigational Site
mi
from
Dallas, TX
Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors
A Phase 1/Phase 2 Study Of CP-751,871 In Patients With Relapsed And/Or Refractory Ewing's Sarcoma Family Of Tumors
Status: Enrolling
Updated: 10/6/2015
Pfizer Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors
A Phase 1/Phase 2 Study Of CP-751,871 In Patients With Relapsed And/Or Refractory Ewing's Sarcoma Family Of Tumors
Status: Enrolling
Updated:  10/6/2015
Pfizer Investigational Site
mi
from
Seattle, WA
Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors
A Phase 1/Phase 2 Study Of CP-751,871 In Patients With Relapsed And/Or Refractory Ewing's Sarcoma Family Of Tumors
Status: Enrolling
Updated: 10/6/2015
Pfizer Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors
A Phase 1/Phase 2 Study Of CP-751,871 In Patients With Relapsed And/Or Refractory Ewing's Sarcoma Family Of Tumors
Status: Enrolling
Updated:  10/6/2015
Pfizer Investigational Site
mi
from
Brisbane,
Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors
A Phase 1/Phase 2 Study Of CP-751,871 In Patients With Relapsed And/Or Refractory Ewing's Sarcoma Family Of Tumors
Status: Enrolling
Updated: 10/6/2015
Pfizer Investigational Site
mi
from
Brisbane,
Click here to add this to my saved trials
Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma
Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-gp100:154-162 TCR-Gene Engineered Lymphocytes and ALVAC Virus Immunization
Status: Enrolling
Updated:  10/6/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma
Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-gp100:154-162 TCR-Gene Engineered Lymphocytes and ALVAC Virus Immunization
Status: Enrolling
Updated: 10/6/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma
Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 F5 TCR-Gene Engineered Lymphocytes and ALVAC Virus Immunization
Status: Enrolling
Updated:  10/6/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma
Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 F5 TCR-Gene Engineered Lymphocytes and ALVAC Virus Immunization
Status: Enrolling
Updated: 10/6/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/6/2015
Hematology Oncology Services of Arkansas
mi
from
Little Rock, AR
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/6/2015
Hematology Oncology Services of Arkansas
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/6/2015
South County Hematology/Oncology
mi
from
Chula Vista, CA
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/6/2015
South County Hematology/Oncology
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/6/2015
Cancer Center Oncology Medical Group
mi
from
La Mesa, CA
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/6/2015
Cancer Center Oncology Medical Group
mi
from
La Mesa, CA
Click here to add this to my saved trials
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/6/2015
UCLA Medical Center
mi
from
Los Angeles, CA
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/6/2015
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/6/2015
UCLA
mi
from
Los Angeles, CA
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/6/2015
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/6/2015
North County Oncology Medical Clinic Inc
mi
from
Oceanside, CA
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/6/2015
North County Oncology Medical Clinic Inc
mi
from
Oceanside, CA
Click here to add this to my saved trials
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/6/2015
Medical Oncology Associates - SD
mi
from
San Diego, CA
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/6/2015
Medical Oncology Associates - SD
mi
from
San Diego, CA
Click here to add this to my saved trials
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/6/2015
Sharp Memorial Hospital Investigational Pharmacy
mi
from
San Diego, CA
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/6/2015
Sharp Memorial Hospital Investigational Pharmacy
mi
from
San Diego, CA
Click here to add this to my saved trials
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/6/2015
Sharp Rees-Stealy
mi
from
San Diego, CA
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/6/2015
Sharp Rees-Stealy
mi
from
San Diego, CA
Click here to add this to my saved trials
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/6/2015
California Pacific Medical Center
mi
from
San Francisco, CA
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/6/2015
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/6/2015
Pacific Hematology Oncology Associates
mi
from
San Francisco, CA
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/6/2015
Pacific Hematology Oncology Associates
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/6/2015
San Francisco Oncology Associates
mi
from
San Francisco, CA
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/6/2015
San Francisco Oncology Associates
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/6/2015
Cohen & Hufford MD's INC
mi
from
San Francisco, CA
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/6/2015
Cohen & Hufford MD's INC
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/6/2015
The Jones Clinic, PC
mi
from
New Albany, MS
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/6/2015
The Jones Clinic, PC
mi
from
New Albany, MS
Click here to add this to my saved trials
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/6/2015
Cleveland Clinic
mi
from
Cleveland, OH
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/6/2015
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/6/2015
Edmond Oncology Center
mi
from
Edmond, OK
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/6/2015
Edmond Oncology Center
mi
from
Edmond, OK
Click here to add this to my saved trials
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/6/2015
OU Medical Center
mi
from
Oklahoma City, OK
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/6/2015
OU Medical Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/6/2015
OU Physician's Building
mi
from
Oklahoma City, OK
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/6/2015
OU Physician's Building
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/6/2015
University of Oklahoma
mi
from
Oklahoma City, OK
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/6/2015
University of Oklahoma
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/6/2015
The Jones Clinic, PC
mi
from
Germantown, TN
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/6/2015
The Jones Clinic, PC
mi
from
Germantown, TN
Click here to add this to my saved trials
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/6/2015
The Vanderbilt Clinic
mi
from
Nashville, TN
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/6/2015
The Vanderbilt Clinic
mi
from
Nashville, TN
Click here to add this to my saved trials
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/6/2015
University of Washington Medical Center
mi
from
Seattle, WA
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/6/2015
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/6/2015
Virginia Mason Medical Center
mi
from
Seattle, WA
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/6/2015
Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/6/2015
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/6/2015
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/6/2015
Centro Oncológico Rosario
mi
from
Rosario,
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/6/2015
Centro Oncológico Rosario
mi
from
Rosario,
Click here to add this to my saved trials
Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer
Phase II Study of Metastatic Cancer That Overexpresses p53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes and Dendritic Cell Vaccination
Status: Enrolling
Updated:  10/6/2015
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
mi
from
Bethesda, MD
Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer
Phase II Study of Metastatic Cancer That Overexpresses p53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes and Dendritic Cell Vaccination
Status: Enrolling
Updated: 10/6/2015
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
mi
from
Bethesda, MD
Click here to add this to my saved trials
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated:  10/6/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated: 10/6/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated:  10/6/2015
Sparks Regional Medical Center
mi
from
Fort Smith, AR
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated: 10/6/2015
Sparks Regional Medical Center
mi
from
Fort Smith, AR
Click here to add this to my saved trials
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated:  10/6/2015
Kaiser Permanente Deer Valley Medical Center
mi
from
Antioch, CA
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated: 10/6/2015
Kaiser Permanente Deer Valley Medical Center
mi
from
Antioch, CA
Click here to add this to my saved trials
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated:  10/6/2015
Kaiser Permanente - Fremont
mi
from
Fremont, CA
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated: 10/6/2015
Kaiser Permanente - Fremont
mi
from
Fremont, CA
Click here to add this to my saved trials
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated:  10/6/2015
Fremont - Rideout Cancer Center
mi
from
Marysville, CA
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated: 10/6/2015
Fremont - Rideout Cancer Center
mi
from
Marysville, CA
Click here to add this to my saved trials
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated:  10/6/2015
Kaiser Permanente-Oakland
mi
from
Oakland, CA
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated: 10/6/2015
Kaiser Permanente-Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated:  10/6/2015
Valley Care Health System - Pleasanton
mi
from
Pleasanton, CA
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated: 10/6/2015
Valley Care Health System - Pleasanton
mi
from
Pleasanton, CA
Click here to add this to my saved trials
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated:  10/6/2015
Kaiser Permanente-Redwood City
mi
from
Redwood City, CA
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated: 10/6/2015
Kaiser Permanente-Redwood City
mi
from
Redwood City, CA
Click here to add this to my saved trials
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated:  10/6/2015
Kaiser Permanente-Richmond
mi
from
Richmond, CA
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated: 10/6/2015
Kaiser Permanente-Richmond
mi
from
Richmond, CA
Click here to add this to my saved trials
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated:  10/6/2015
Kaiser Permanente Roseville
mi
from
Roseville, CA
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated: 10/6/2015
Kaiser Permanente Roseville
mi
from
Roseville, CA
Click here to add this to my saved trials
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated:  10/6/2015
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated: 10/6/2015
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Click here to add this to my saved trials
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated:  10/6/2015
Kaiser Permanente-South Sacramento
mi
from
Sacramento, CA
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated: 10/6/2015
Kaiser Permanente-South Sacramento
mi
from
Sacramento, CA
Click here to add this to my saved trials
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated:  10/6/2015
Kaiser Permanente - Sacramento
mi
from
Sacramento, CA
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated: 10/6/2015
Kaiser Permanente - Sacramento
mi
from
Sacramento, CA
Click here to add this to my saved trials
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated:  10/6/2015
Kaiser Permanente-San Francisco
mi
from
San Francisco, CA
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated: 10/6/2015
Kaiser Permanente-San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated:  10/6/2015
Kaiser Permanente-Santa Teresa-San Jose
mi
from
San Jose, CA
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated: 10/6/2015
Kaiser Permanente-Santa Teresa-San Jose
mi
from
San Jose, CA
Click here to add this to my saved trials
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated:  10/6/2015
Kaiser Permanente San Leandro
mi
from
San Leandro, CA
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated: 10/6/2015
Kaiser Permanente San Leandro
mi
from
San Leandro, CA
Click here to add this to my saved trials
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated:  10/6/2015
Kaiser Permanente San Rafael
mi
from
San Rafael, CA
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Status: Enrolling
Updated: 10/6/2015
Kaiser Permanente San Rafael
mi
from
San Rafael, CA
Click here to add this to my saved trials